Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) has announced continued progress in intermediate-scale manufacturing and process development for key precursor components of ONC010, the company's lead nanoparticle-formulated oncology candidate. The candidate is currently advancing through investigational new drug (IND)-enabling development, positioning the company for regulatory submissions and first-in-human clinical trials.
The manufacturing scale-up activities, conducted in collaboration with Dalton Pharma Services as part of Onco's integrated chemistry, manufacturing, and controls (CMC) strategy, are focused on process optimization, analytical characterization, and manufacturing reproducibility. These efforts are designed to support future Good Manufacturing Practice (GMP) production, ensuring regulatory readiness and enabling planned first-in-human clinical development in Australia.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, with a mission to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology targeting solid tumors. For more information, visit Onco-Innovations.
The advancement of ONC010 represents a significant step forward in the company's pipeline, as nanoparticle-formulated therapies offer the potential for targeted drug delivery and improved efficacy in solid tumor treatment. The ongoing manufacturing scale-up is critical for ensuring consistent and high-quality production of the candidate, which is essential for regulatory approval and eventual commercialization.
Onco-Innovations' progress in manufacturing aligns with broader industry trends toward precision medicine and advanced drug delivery systems. By optimizing the production process for ONC010, the company aims to reduce manufacturing costs and increase scalability, which could facilitate broader access to the therapy if approved.
The company's focus on regulatory readiness is underscored by its plans for first-in-human clinical development in Australia, a jurisdiction known for its efficient regulatory pathways. Successful completion of IND-enabling studies and manufacturing scale-up will be key milestones for Onco-Innovations as it seeks to bring ONC010 to patients in need.
For more details on the press release, visit this link.
